Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.93 -1.12%

-$0.34 today

Market cap
$1.76B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.64M

Average 0.64M

Returns on capital

Stoke Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-2.0%

avg 20.6%

ROIC

-5.7%

avg -62.2%

ROA

-1.6%

avg -47.4%

Analysis

ROA is currently the strongest return metric at -1.6% versus its period average of -47.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Ian F. Smith

Chief Executive Officer & DirectorUSD 1.41M60129.00K0.21%

Jason Hoitt

Chief Patient OfficerUSD 815.42K4810.28K0.02%

Thomas Edward Leggett

Chief Financial OfficerUSD 804.02K49——

Edward Kaye

Advisor & DirectorUSD 736.38K77——

Barry S. Ticho FACC

Chief Medical OfficerUSD 726.5K66——

Adrian R. Krainer

Co-Founder & Independent DirectorUSD 45K6717.79K0.03%

Thomas McCauley

Chief Scientific Officer—57225.00K0.36%

Jonathan Allan

Corporate Secretary, Compliance Officer & General Counsel—3620.60K0.03%

Isabel Aznarez

Co-Founder & CTO—54——

Sara Den Besten

Chief People Officer————

Susan Willson

Vice President of Corporate Communications————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

79

$7.88M

Net Transaction Value

−$7.88M

Net selling

Most Active

Ticho Barry

28 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 2, 26

Ticho Barry

Direct

Sell$184.5K
Nov 2, 26

Ticho Barry

Direct

Sell$5.4K
Oct 2, 26

Allan Jonathan

Direct

Sell$16.5K
Oct 1, 26

Ticho Barry

Direct

Sell$27.5K
Sep 1, 26

Ticho Barry

Direct

Sell$120.4K
Sep 1, 26

Ticho Barry

Direct

Sell$49.7K
Aug 18, 26

Ticho Barry

Direct

Sell$7.9K
Aug 18, 26

Ticho Barry

Direct

Sell$144.8K
Aug 18, 26

Kaye Edward M. MD

Direct

Sell$381.8K
Aug 18, 26

Kaye Edward M. MD

Direct

Sell$20.7K

1–10 of 79

Summary

Insiders reported 0 buys worth $0.00 and 79 sells worth $7.88M over the last 12 months. That adds up to net selling of $7.88M. Ticho Barry was the most active insider with 28 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/A+145.9%
+27.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +145.9% over three years. Forward estimates point to Revenue at +27.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Stoke Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about STOK's management, answered from reported figures.

Who manages STOK?

Stoke Therapeutics, Inc. (STOK) lists 11 active executives. The top listed executive is Thomas McCauley, Chief Scientific Officer.

Are STOK insiders buying or selling?

Recent insider activity shows net buying of $28.54M.